Journal: eLife
Article Title: Cap-independent co-expression of dsRNA-sensing and NF-κB pathway inhibitors enables controllable self-amplifying RNA expression with reduced immunotoxicity
doi: 10.7554/eLife.105978
Figure Lengend Snippet: ( a ) Phosphorylated eIF2α levels examined by in-cell western (n=6). Conventional saRNA increased eIF2α phosphorylation, while E3 and E3-NSs-L* did not. Data are normalized to total eIF2α and presented as fold-change relative to mock transfection. ( b ) Total eIF2α levels examined by in-cell western (n=5). E3-NSs-L* increased total eIF2α. Data are normalized to CellTag and presented as fold-change relative to mock transfection. ( c ) Phosphorylated eIF4E levels, normalized to total eIF4E, examined by in-cell western (n=6). All constructs reduced eIF4E phosphorylation. ( d ) Total eIF4E levels, normalized to CellTag, examined by in-cell western (n=6). No significant differences were revealed (F(3,15) = 1.207, p=0.3410). For all panels: Statistical significance was determined by one-way RM ANOVA and Tukey’s multiple comparison test. *p<0.05, **p<0.01, ***p<0.001. The mock transfection control data are also used in . Connecting lines indicate responses from the same biological replicate. Figure 3—source data 1. Numerical data used to generate the plots in .
Article Snippet: The following primary antibodies were used: Phospho-eIF2α (Ser51) (D9G8) XP rabbit monoclonal (1:200, #3398, Cell Signaling Technology), eIF2α (L57A5) mouse monoclonal (1:200, #2103, Cell Signaling Technology), PKR rabbit polyclonal (1:500, #18244-1-AP, Proteintech), Phospho-eIF4E (S209) rabbit monoclonal (1:200, #ab76256, Abcam), eIF4E mouse monoclonal (5D11) (1:200, #MA1-089, Invitrogen), and FAP (73.3) mouse monoclonal (20 μg/mL, #BE0374, InVivoMAb).
Techniques: In-Cell ELISA, Phospho-proteomics, Transfection, Construct, Comparison, Control